In 2018, I was elected President of the Israeli Society of Gene and Cell Therapy, I am the chair of the International Conference on Lymphocyte Engineering (ICLE) and I am an invited guest editor of “Human Gene Therapy”.
I am a gene therapist. My personal mission is to devise technologies which advance human health and wellbeing. I have a proven track record of inventing bold, “out of the box”, novel therapeutic approaches and seeing them through from inception to proof of concept, from basic science to curing animal models and from the academic lab to the pharma. I am determined to bring my inventions to the patients in need.
In august 2014 I co-founded the gene therapy start-up company LogicBio therapeutics. LogicBio’s mission is to develop durable cures for serious rare diseases based on the technology I developed during my Stanford postdoc years. In April 2016 I was appointed senior lecturer at the Department of Biochemistry and Molecular Biology at Tel Aviv University. My academic goals are disjoint from the company’s mission. While my company seeks to treat rare genetic disorders, my academic lab focuses on the immunotherapy of cancer and autoimmune diseases. In particular, my academic lab is developing revolutionary new methods for the engineering of B cells as well as T cells for safe, effective and scalable immunotherapy. I was able to secure competitive grant funding from the Israeli Science Foundation, the Reut foundation as well as ERC young investigator grant.
There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.
There is a registration fee to attend the conferences. To visit the exhibition is free.